References
- 1. Vardiman JW, Brunning RD, Arber DA, Lebean MM, Porurt A, Telferi A, et al. Introduction and Overview of the Classification of the Myeloid Neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC, Lyon. 2008; 18-49.
- 2. Campbell PJ, Green AR. The myeloproliferative disorders.N Engl J Med. 2006 Dec; 355(23):2452-66. DOI: 10.1056/NEJMra063728.
- 3. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012 Dec;2012(1):571-81.
- 4. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013 Mar;122(13):2176-84. DOI: 10.1182/blood-2013-03-460154.
- 5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023.
- 6. Marchetti M, Castoldi E, Spronk HMH, van Oerle R, Baldicci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008 Nov;112(10):4061-8. DOI: 10.1182/ blood-2008-06-164087.
- 7. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia and idiopatic myelofibrosis: a systematic review. Thromb Res. 2009 Sep;124(4):409-17. DOI: 10.1016/j.thromres.2009.02.004.
- 8. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, et al. Global coagulation in myeloproliferative neoplasms. Annals of Hematology. 2013 Dec;92(12):1633-9. DOI: 10.1007/s00277-013-1834-x.
- 9. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011 Feb;127(Suppl3): S21-5. DOI: 10.1016/S0049-3848(11)70007-X.
- 10. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-8.
- 11. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zang L. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005 Sep;106(6):2162-68. DOI: 10.1182/ blood-2005-03-1320.
- 12. Ten Caten H. Thrombin generation in clinical conditions. Thromb Res. 2012 Mar;126(3):367-70. DOI: 10.1016/j.thromres.2011.10.017
- 13. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010 Sep(3);126:238-42. DOI: 10.1016/j.thromres.2010.06.025.
- 14. Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009 Jul;94(7):911-8. DOI: 10.3324/haematol.13774.
- 15. Campbell PJ, MacLean C, Beer PA, Buck G, Weathley K, Kiladjian JJ et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012 Aug;120(7):1409-11. DOI: 10.1182/ blood-2012-04-424911.
- 16. Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarini M. Increase in leucocyte count over tome predicts thrombosis in patients with low-risk essential thrombocythemia. Thromb Haemost. 2009 Sep;7(9):1587-9. DOI: 10.1111/j.1538-7836.2009.03531.x.
- 17. Panova-Noeva M, Marcetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, et al. Jak2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011Sep;118(9):2599-601. DOI: 10.1182/blood-2011-02-339655.
- 18. Olteanu AL, Mihaila RG, Catana AC, Flucus O, Bus C, Mihalache M. Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms. Rev Romana Med Lab. 2015;23(2):169-77. DOI:10.1515/rrlm-2015-0012.
- 19. Carrobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responce by European Leukemianet criteria.Blood. 2010 Aug;116(7):1051-5. DOI: 10.1182/ blood-2010-03-272179.
- 20. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med. 2005 Jul;353(1):33-45. DOI: 10.1056/ NEJMoa043800.
- 21. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J,Kvasnicka HM,et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar;121(10):1720-8. DOI: 10.1182/blood-2012-07-443770.
- 22. Barbui T, Finazzi G, Carrobio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization – essential thrombocythemia (IPSET-thrombosis). Blood. 2012 Dec; 120(26):5128-33. DOI: 10.1182/blood-2012-07-444067.
- 23. Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014 Jan;99(1):32-40. DOI: 10.1007/s12185-013-1475-9.